Abstract
Background: The optimal pretreatment strategy for patients with ovarian endometrioma (OEM) undergoing in vitro fertilization (IVF)
remains controversial, particularly among those with a normal ovarian response. Letrozole (LE) has been proposed to modulate the
ovarian hormonal environment and improve ovarian stimulation outcomes. However, its clinical value in this patient population has not
been fully established. We assessed the clinical value of pretreatment with LE in combination with a gonadotropin-releasing hormone
agonist (GnRHa) in patients with OEM and normal ovarian response undergoing IVF. Methods: In this retrospective study, 71 patients
with OEM and normal ovarian response who underwent IVF-embryo transfer (IVF-ET) were initially enrolled and assigned to the GnRHa
+ LE group (n = 36) or the GnRHa group (n = 35). After one patient was excluded from each group, 35 patients in the GnRHa + LE
group and 34 patients in the GnRHa group were included in the final transfer-cycle analysis. During controlled ovarian stimulation,
patients received pretreatment with GnRHa (3.75 mg) either alone or in combination with LE (2.5 mg) and were accordingly allocated
to the GnRHa group or the GnRHa + LE group. Between-group differences were evaluated regarding baseline characteristics, ovarian
stimulation profiles, and reproductive outcomes. Results: The total gonadotropin dose was significantly lower in the GnRHa + LE group
and was accompanied by reduced serum estradiol levels on the trigger day ( p < 0.01). This group also demonstrated increased numbers
of retrieved and metaphase II oocytes (all p < 0.01), as well as improved fertilization rates ( p = 0.02) and day-3 high-quality embryo rates
(p < 0.05). Stimulation duration, cleavage rate, progesterone levels, embryo transfer number, endometrial thickness, and fresh embryo
transfer cancellation rates did not differ significantly between groups (all p > 0.05). The clinical pregnancy rate was significantly higher
in the GnRHa + LE group ( p = 0.04). The implantation rate was significantly higher in the GnRHa + LE group than in the GnRHa
group (p = 0.04), whereas the early miscarriage rate was comparable between the two groups ( p = 0.82). Reduction in maximal ovarian-
endometriotic-cyst diameter was significantly greater in the GnRHa + LE group ( p = 0.04). Conclusions: Combined pretreatment with
LE and GnRHa may enhance ovarian response efficiency and improve IVF-ET outcomes among women with OEM who exhibit a normal
ovarian response.
Keywords
gonadotropin-releasing hormone agonist; infertility; in vitro fertilization; letrozole; normal ovarian response; ovarian en-
dometrioma
1. Introduction
Endometriosis is a chronic estrogen-dependent gyne-
cological disorder characterized by the ectopic presence of
functional endometrial-like tissue outside the uterine cav-
ity, and is commonly associated with dysmenorrhea, pelvic
pain, infertility, and impaired organ function. It affects
approximately 10%–20% of women of reproductive age,
with up to 50% experiencing infertility [ 1]. Moreover, be-
yond its clinical manifestations, endometriosis is associated
with a compromised reproductive microenvironment, in-
cluding chronic inflammation, immune dysregulation, and
impaired endometrial receptivity, which may adversely af-
fect assisted reproductive technology outcomes.
Ovarian endometrioma (OEM) is the most common
subtype among infertile women, with approximately 17%–
44% of patients undergoing assisted reproductive treat-
ment, including in vitro fertilization and embryo transfer
(IVF-ET), being affected. Ovarian endometriomas may ad-
versely affect fertility and reproductive outcomes in women
with endometriosis [2]. In addition, OEM has been reported
to adversely affect IVF outcomes by decreasing oocyte
quality, reducing fertilization rates, impairing embryo de-
velopment, and increasing the risk of implantation failure
and early pregnancy loss.
Gonadotropin-releasing hormone agonists (GnRHa)
remain a key medical therapy for endometriosis and are
widely integrated into IVF-ET protocols. Sallam et al. [ 3]
reported that 3–6 months of GnRHa pretreatment increased
clinical pregnancy rates in women with endometriosis by
nearly fourfold. Long-acting GnRHa before embryo trans-
fer has also been shown to lower early miscarriage rates [4].
However, evidence regarding GnRHa-induced reduction of
ovarian endometriotic cysts is inconsistent, likely due to in-
sufficient suppression of extragonadal estrogen production
[5].
Mechanistically, GnRHa treatment initially induces a
transient flare-up effect followed by downregulation of pi-
tuitary gonadotropin secretion, leading to profound hypoe-
strogenism and suppression of endometriotic lesion activ-
ity. This hypoestrogenic state contributes to reduced lesion
proliferation, decreased inflammatory cytokine production,
and improved pelvic environment [ 1,5].
Letrozole (LE), a selective aromatase inhibitor, sup-
presses both intra- and extra-ovarian estrogen biosynthe-
sis, thereby inhibiting estrogen-dependent lesion growth.
In one study, three months of high-dose LE (5 mg/day)
combined with a progestin reduced mean cyst diameter by
about 50% and cyst volume by 75% [ 6]. At the molec-
ular level, LE inhibits the aromatase enzyme responsible
for the peripheral conversion of androgens to estrogens,
thereby reducing both systemic and local estrogen concen-
trations. This dual suppression is particularly relevant in
endometriosis, where ectopic lesions exhibit aberrant aro-
matase expression and local estrogen production [ 6].
Given the complementary mechanisms of GnRHa and
LE, we hypothesized that combined pretreatment would
enhance IVF outcomes in OEM patients. Specifically,
whereas GnRHa suppresses ovarian estrogen production
via pituitary downregulation, LE further inhibits peripheral
and local estrogen synthesis, potentially resulting in more
complete estrogen deprivation and improved control of en-
dometriotic activity. This study therefore evaluated the
clinical value of GnRHa plus LE pretreatment in normal-
responder women with OEM who were undergoing IVF-
ET.
2. Materials and Methods
2.1 Study Sample
A total of 125 patients with OEMs and normal ovarian
response who underwent IVF-ET at the Reproductive Cen-
ter of Xuzhou Central Hospital between March 2023 and
March 2025 were initially assessed for eligibility. OEM
was not considered the sole cause of infertility in all cases;
instead, all patients had a confirmed diagnosis of OEM, al-
though additional infertility factors (such as tubal or male
factors) could coexist. Of these, 54 patients were excluded
for the following reasons: age 35 years (n = 21),
failure to meet the predefined criteria for normal ovarian re-
sponse (n = 8), prior surgery for endometriosis (n = 9), uter-
ine abnormalities, endometrial disorders, or hydrosalpinx
potentially affecting implantation (n = 11), and total motile
sperm count <5 × 10 6 in the male partner (n = 5).
Ultimately, 71 patients were enrolled and assigned to
either the GnRHa + LE group (n = 36) or the GnRHa group
(n = 35), according to whether LE pretreatment was used.
One patient in each group was subsequently excluded (due
to elevated progesterone level on trigger day in the GnRHa
+ LE group and personal reasons in the GnRHa group),
leaving 35 and 34 patients, respectively, for the final anal-
ysis (Fig. 1).
2.2 Inclusion Criteria
The inclusion criteria were: (1) age between 23 and
35 years; (2) diagnosed with OEMs only; other subtypes
of endometriosis (e.g., deep infiltrating endometriosis or
peritoneal endometriosis) were not included. (3) no previ-
ous surgical history related to endometriosis; OEMs were
diagnosed by experienced clinicians using transvaginal ul-
trasonography, according to the International Ovarian Tu-
mor Analysis (IOTA) consensus criteria [ 7], characterized
by cysts with regular margins and homogeneous low-level
“ground-glass” echogenicity; (4) normal ovarian response
meeting the following criteria [ 8]: (a) a basal follicle-
stimulating hormone (FSH) level below 10 IU/L; (b) bi-
lateral antral follicle count (AFC) between 7 and 14; (c)
anti-Müllerian hormone (AMH) between 1.0 ng/mL and 4.0
ng/mL; (d) no history of ovarian-stimulation-cycle cancel-
lation prior to oocyte retrieval due to poor or excessive ovar-
ian response.
2.3 Exclusion Criteria
The exclusion criteria were: (1) either partner pre-
senting with chromosomal abnormalities; (2) uterine ab-
normalities (e.g., congenital malformations, adenomyosis,
or leiomyoma), endometrial lesions (e.g., endometritis,
polyps, or intrauterine adhesions), or hydrosalpinx that may
affect embryo implantation; (3) endocrine, immunologic, or
metabolic disorders such as thyroid disease, diabetes melli-
tus, hyperprolactinemia, or polycystic ovary syndrome; (4)
male factor infertility, particularly severe male factor de-
fined as total motile sperm count <5 × 10 6 in the male part-
ner [ 9], thereby minimizing the potential confounding ef-
fect of male-related factors on IVF outcomes; (5) severe
systemic diseases, including major organ dysfunction, ma-
lignancy, or a history of thromboembolic events; (6) poor
ovarian responders and high ovarian responders, were ex-
cluded to ensure a homogeneous population of normal ovar-
ian responders.
This retrospective study was approved by the Ethics
Committee of our hospital. The requirement for written
informed consent was waived due to the retrospective na-
ture of the study. Ethical approval was obtained after com-
pletion of patient follow-up, and all data were anonymized
prior to analysis.
2.4 Controlled Ovarian Stimulation Protocols
Patients were not randomly assigned in this retrospec-
tive study; instead, the allocation to each treatment group
was based on clinical decision-making, considering physi-
cian preference and patient-specific conditions at the time
of treatment. Two different controlled ovarian stimulation
protocols were implemented as described below:
GnRHa group (n = 35): On menstrual cycle days 1–3,
patients received an injection of triptorelin acetate 3.75 mg,
s.c. (Decapeptyl, Ferring Pharmaceuticals SA, Saint-Prex,
Switzerland). The injection was repeated after 30 days for
a total of two doses.
2
Fig. 1. Flow diagram of the study . GnRHa, gonadotropin-releasing hormone agonist; LE, letrozole.
GnRHa + LE group (n = 36): On menstrual cycle
days 1–3, patients underwent the same GnRHa pretreatment
as described above and received 2.5 mg LE (Jiangsu Hen-
grui Pharmaceuticals Co., Ltd., 231205KL, Lianyungang,
Jiangsu, China) orally once daily for five consecutive days.
Thirty days after the last GnRHa injection, vaginal ul-
trasonography was performed to assess antral follicle num-
ber and size. Serum concentrations of fFSH, luteinizing
hormone (LH), and estradiol (E 2) were assessed. Pituitary
downregulation [ 10] was defined as the presence of folli-
cles with a diameter ≤10 mm, accompanied by serum FSH
and LH levels below 5 mIU/mL and an E2 level <50 pg/mL.
Controlled ovarian stimulation was then initiated with
recombinant FSH (r-FSH, Gonal-F, Merck Serono GmbH,
BA089041/BA096091, Darmstadt, Germany) at 150–225
IU combined with recombinant LH (r-LH, Luveris, Merck
Serono GmbH, AU035478/AU043747, Darmstadt, Ger-
many) at 75 IU daily. Dosages were adjusted accord-
ing to individual ovarian response. When at least one
follicle reached ≥18 mm or two follicles reached ≥17
mm, ovulation was triggered using recombinant human
chorionic gonadotropin (r-hCG, Ovitrelle, Merck Serono,
BA091066/BA096099, Modugno, Bari, Italy) 0.25 mg, s.c.
Oocyte collection was carried out 36–37 hours after trigger
administration, guided by transvaginal ultrasonography.
2.5 Fertilization, Embryo Transfer , and Luteal Support
Semen samples were produced from the male part-
ners by masturbation on the day of oocyte retrieval and col-
lected. All cycles in this study were performed using con-
ventional IVF, as patients with severe male-factor infertil-
ity were excluded. Fertilization was assessed by the pres-
ence of two pronuclei (2PN) at 16–18 h after insemination.
Embryo morphology was assessed according to the Istanbul
consensus [11].
Patients in the downregulation group received proges-
terone (Zhejiang Xianju Pharmaceutical Co., Ltd., FB2439,
Xianju County, Taizhou, Zhejiang, China), 60 mg/day i.m.,
and oral estradiol-dydrogesterone tablets (Femoston, Ab-
bott Biologicals B.V ., 370364/374233, Olst, Netherlands;
containing 2 mg estradiol and 10 mg dydrogesterone, twice
daily) for luteal-phase support.
On day 3 post-fertilization, embryo transfer (ET) was
performed under ultrasound guidance, with the number of
embryos (one or two) determined according to endometrial
thickness, serum hormone profiles, and embryo quality.
Remaining viable embryos were cryopreserved for frozen-
thawed embryo transfer (FET) if fresh transfer was not car-
ried out.
2.6 Pregnancy Assessment and Follow-Up
Serum β-human chorionic gonadotropin (β-hCG) con-
centrations were assessed 14 days following ET. Levels ≤5
mIU/mL indicated implantation failure. Clinical pregnancy
was diagnosed when transvaginal ultrasonography at 28–35
days after ET demonstrated both a gestational sac and fetal
cardiac activity.
2.7 Outcome Measures
Baseline characteristics were: age; duration of infer-
tility; body mass index (BMI); AFC; AMH; basal hormone
levels (FSH, E 2); and mean maximum diameter of OEMs.
Stimulation and laboratory parameters were: dura-
tion and total dose of gonadotropin; number of retrieved
oocytes; number of metaphase II (MII) oocytes; fertiliza-
tion rate; cleavage rate; day-3 high-quality embryo rate;
serum E 2 and progesterone levels on trigger day; endome-
trial thickness; number of embryos transferred; and fresh
embryo-transfer-cancellation rate.
3
Pregnancy outcomes were: mean maximum diameter
of OEMs on trigger day; implantation rate; clinical preg-
nancy rate; and early miscarriage rate.
2.8 Definitions of Indicators
The indicators were defined according to previously
published studies [11,12,13].
● The total number of oocytes retrieved referred to all
oocytes collected during the oocyte retrieval procedure.
● MII oocytes were defined as mature oocytes char-
acterized by the extrusion of the first polar body.
● The fertilization rate was calculated as the pro-
portion of oocytes successfully fertilized among all MII
oocytes.
● The cleavage rate represented the percentage of em-
bryos that underwent cleavage relative to the number of nor-
mally fertilized oocytes.
● The proportion of high-quality embryos on day 3
was defined as the number of good-quality embryos divided
by the total number of cleaved embryos derived from nor-
mally fertilized (2PN) zygotes.
● The cancellation rate of fresh embryo transfer cy-
cles was calculated based on the proportion of cycles in
which embryo transfer was not performed among all oocyte
retrieval cycles.
● The implantation rate was defined as the ratio of
successfully implanted embryos to the total number of em-
bryos transferred.
● The clinical pregnancy rate was calculated as the
proportion of cycles resulting in clinical pregnancy among
all embryo transfer cycles.
● Early miscarriage rate = (number of early miscar-
riages ÷ number of clinical pregnancies) × 100%.
2.9 Statistical Analysis
All statistical analyses were carried out with SPSS
19.0 (IBM Corp., Armonk, NY , USA). Continuous vari-
ables were summarized as mean ± SD and analyzed using
the independent samples t-test for between-group compar-
isons. Before applying the t-test, the normality of continu-
ous variables was assessed using the Shapiro–Wilk test, and
homogeneity of variances was evaluated using Levene’s
test. If the assumptions for the t-test were not met, non-
parametric tests (Mann–Whitney U, Chi-square, Fisher’s
exact) were used, as appropriate. With the actual analyzed
sample sizes of 35 and 34, the post hoc statistical power
to detect differences in embryos transferred and endome-
trial thickness was approximately 12.8% and 5.7%, respec-
tively, using a two-tailed, two-sample t-test with unequal
variances at a significance level of 0.05. A p-value ≤ 0.05
was considered statistically significant.
3. Results
3.1 Baseline Characteristics of the Study Population
Baseline demographic and clinical parameters were
comparable between the two groups. No significant dif-
ferences were observed in age, duration of infertility, BMI,
AFC, AMH, basal FSH, basal E 2 levels, or the mean maxi-
mal diameter of OEMs (all p > 0.05) (Table 1).
3.2 Ovarian Stimulation Outcomes and Embryological
Characteristics
Compared with the GnRHa protocol alone, patients
receiving the combined GnRHa + LE regimen required a
lower total dose of gonadotropin and exhibited reduced
serum E 2 concentrations on the day of trigger (both p
< 0.05). In contrast, the GnRHa + LE group yielded a
greater number of retrieved and MII oocytes, along with
improved fertilization outcomes and a higher proportion of
high-quality embryos on day 3 ( p
0.05) (Table 2).
3.3 Comparison of Treatment Outcomes and Pregnancy
Results
Fresh embryo transfer was carried out in 35 cycles in
the GnRHa + LE group and in 34 cycles in the GnRHa
group. Baseline transfer characteristics, including the num-
ber of embryos transferred, endometrial thickness on the
transfer day, and the rate of ET cancellation, were compa-
rable between the two groups (all p > 0.05). Compared with
the GnRHa group, the GnRHa + LE group demonstrated a
significantly higher clinical pregnancy rate, along with an
increased implantation rate (all p < 0.05) and a compara-
ble incidence of early miscarriage ( p = 0.82). In addition,
the mean maximum diameter of OEMs was significantly
smaller in the GnRHa + LE group than in the GnRHa group
after pretreatment (p < 0.05) (Table 3).
4. Discussion
Endometriosis is an estrogen-dependent disease in
which increased estrogen sensitivity and progesterone re-
sistance play critical roles in onset and progression. The
disease has an insidious onset and begins to impair fertility
even at its early stage, with an average diagnostic delay of
approximately 10 years [ 14]. A study has shown that 22–
63% of women with unexplained infertility who undergo
laparoscopy are found to have endometriosis [ 15]. As the
disease progresses, ectopic endometrial tissue may invade
the pelvic cavity, ovaries, or peritoneum, leading to infer-
tility through multiple mechanisms, including altered coital
frequency, ovulatory dysfunction, impaired tubal function,
reduced embryo quality, and decreased endometrial recep-
tivity [16]. In addition, endometriosis-associated peritoneal
fluid may negatively affect sperm function [ 17]. An ex-
perimental study showed that peritoneal fluid from women
with moderate to severe endometriosis can impair sperm
motility, potentially due to elevated levels of reactive oxy-
gen species and inflammatory cytokines (e.g., tumor necro-
sis factor-alpha [TNF-α], interleukin-6 [IL-6], interleukin-
4
Table 1. Baseline characteristics of the study groups .
V ariable GnRHa + LE group GnRHa group p V alue
Cycles (n) 36 35
Age (years) 30.42 ± 3.55 (23–34) 29.03 ± 2.95 (25–35) 0.08
Type of Infertility, n (%) 0.73
Primary 22 (61.11%) 20 (57.14%)
Secondary 14 (38.89%) 15 (42.86%)
Duration of Infertility (years) 3.38 ± 1.00 3.11 ± 1.13 0.31
BMI (kg/m2) 22.54 ± 1.99 21.90 ± 1.79 0.16
AFC (n) 10.36 ± 2.67 10.71 ± 2.52 0.57
AMH (ng/mL) 2.69 ± 0.70 2.63 ± 0.62 0.70
Basal FSH (mIU/mL) 7.74 ± 1.36 7.34 ± 1.78 0.29
Basal E2 (pg/mL) 41.00 (32.00, 65.00) 40.00 (33.00, 60.95) 0.74
Max diameter (mm) 33.67 ± 5.86 32.13 ± 5.07 0.24
Note: BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; Basal FSH, basal
follicle-stimulating hormone; Basal E2, basal estradiol; Max diameter, mean maximum diameter of ovarian
endometriomas. Data are presented as mean ± SD, median (IQR), or n (%), as appropriate.
Table 2. Ovarian stimulation outcomes and embryological variables in the two groups [(mean ± SD), %] .
V ariable GnRHa + LE group GnRHa group p V alue
Cycles (n) 36 35
Stimulation Days 9.97 ± 1.70 9.83 ± 1.62 0.72
Total Gonadotropin Dose (IU) 2182 ± 406.6 2705 ± 416.6 <0.01
Oocytes Retrieved 9.11 ± 2.52 6.97 ± 1.86 <0.01
MII Oocytes 6.75 ± 2.37 4.80 ± 1.55 <0.01
Fertilization Rate (%) 87.24 (212/243) 77.38 (130/168) 0.01
Cleavage Rate (%) 90.09 (191/212) 87.69 (114/130) 0.12
Day 3 high-quality embryo rate (%) 60.73 (116/191) 49.12 (56/114) <0.05
E2 (pg/mL) 1981 ± 556.10 2924 ± 730.50 <0.01
P (ng/mL) 0.83 ± 0.34 0.91 ± 0.18 0.20
Note: MII, metaphase II; E 2, estradiol; P , progesterone.
Table 3. Treatment and pregnancy outcomes in the two groups [(mean ± SD), %] .
V ariable GnRHa +LE group GnRHa group p V alue
Total cycles (n) 36 35
Fresh embryo transfer cycles (n) 35 34
Max diameter (mm) 27.14 ± 5.65 29.72 ± 4.68 0.04
Embryos Transferred 1.51 ± 0.51 1.41 ± 0.50 0.40
Endometrial Thickness (mm) 10.86 ± 4.33 10.66 ± 2.01 0.81
Fresh embryo transfer cancellation rate (%) 2.78 (1/36) 2.86 (1/35) 1.00
Implantation Rate (%) 41.51 (22/53) 22.92 (11/48) 0.04
Clinical Pregnancy Rate (%) 57.14 (20/35) 32.35 (11/34) 0.04
Early Miscarriage Rate (%) 15.00 (3/20) 18.18 (2/11) 1.00
Note: Embryos transferred and endometrial thickness were analyzed among fresh embryo
transfer cycles (n = 35 in the GnRHa + LE group and n = 34 in the GnRHa group). The fresh
embryo transfer cancellation rate was calculated based on all initiated cycles (n = 36 and n
= 35, respectively).
8 [IL-8]), which may interfere with sperm capacitation and
acrosome reaction [ 18]. However, the application of as-
sisted reproductive technology enables the majority of pa-
tients to attain favorable reproductive outcomes.
OEMs represent an advanced stage of the disease. The
cysts can impair ovarian function through mechanical com-
pression and the secretion of inflammatory cytokines, reac-
tive oxygen species, and free iron, thereby reducing ovarian
responsiveness, impairing oocyte development, and com-
promising embryo quality, which ultimately affects IVF-
ET outcomes [ 2]. An in vitro study has demonstrated that
exposure of parthenogenetically activated oocytes to follic-
5
ular fluid from patients with OEMs significantly increases
oocyte fragmentation and cell death, thereby impairing em-
bryonic development [19].
GnRHa is among the most widely used classes of med-
ications for the treatment of endometriosis. A GnRHa binds
to gonadotropin-releasing hormone receptors on the ante-
rior pituitary with high affinity, initially producing a “flare-
up effect” that transiently elevates FSH and LH levels and
promotes follicular development. With prolonged adminis-
tration, however, receptor desensitization and downregula-
tion occur, leading to suppression of gonadotropin secretion
and reduced estrogen levels. As a result, ectopic endome-
trial tissue undergoes atrophy due to estrogen deprivation,
thereby relieving symptoms and improving fertility in pa-
tients with endometriosis [ 20].
Most studies have demonstrated that pretreatment
with GnRHa for 3–6 months before Assisted Reproductive
Technology (ART) improves clinical outcomes in patients
with advanced endometriosis (stage III–IV), although its
benefit in mild disease remains controversial [ 21,22]. The
mechanisms by which GnRHa enhances IVF outcomes are
multifactorial. GnRHa reduces the expression of vascu-
lar endothelial growth factor, tissue factor, and protease-
activated receptor 2 in ectopic endometrium, thereby in-
hibiting angiogenesis and reducing cell adhesion and inva-
sion [23]. In addition, GnRHa decreases the production of
cytotoxic factors in follicular fluid, reduces oxidative stress,
and improves oocyte quality. After three months of GnRHa
treatment, the concentrations of TNF-α and 8-hydroxy-2′-
deoxyguanosine in follicular fluid are significantly reduced,
whereas melatonin levels and fertilization rates are higher
[24].
GnRHa also improves endometrial receptivity by pro-
moting the development of pinopodes. Li et al. [ 25]
reported that GnRHa pretreatment downregulated miR-
124-3p expression and upregulated IL-6, IL-11, Leukemia
Inhibitory Factor (LIF), and integrin αvβ3 in the en-
dometrium, which favored early embryo implantation. Fur-
thermore, GnRHa enhanced subendometrial blood perfu-
sion and improved the pelvic inflammatory environment
[26]. However, whether GnRHa reduces the size of en-
dometriotic lesions remains unclear. GnRHa primarily sup-
presses ovarian estrogen production but does not affect es-
trogen derived from ectopic endometrial tissue, adrenal cor-
tex, or peripheral aromatization, which may explain why
some cases are resistant to ovarian suppression [ 5].
As a third-generation aromatase inhibitor, LE sup-
presses estrogen production at both central and peripheral
levels, thereby establishing a hormonal milieu that more
closely resembles physiological conditions. A study has
shown that LE effectively reduces serum E 2 levels on the
day of trigger and lowers E 2 production per mature folli-
cle without compromising ovulation-induction outcomes,
thereby reducing estrogen exposure and potentially limiting
disease progression. It is widely considered a relatively safe
option for ovulation induction when fertility preservation is
required in individuals with hormone-sensitive gynecologic
malignancies [27].
LE has also been shown to improve ovarian re-
sponse and endometrial receptivity. Among women with
poor ovarian response, co-administration of LE with go-
nadotropins was associated with increased yields of re-
trieved oocytes, MII oocytes, and high-quality embryos
compared with gonadotropin stimulation alone [28]. In hor-
mone replacement embryo-transfer cycles, the addition of
LE was linked to increased pregnancy rates, likely due to
enhanced endometrial receptivity through molecular mech-
anisms [ 29]. An animal study has demonstrated that LE
increased the expression of αvβ3 integrin and Homeobox
A10 (HOXA10), two markers of endometrial receptivity,
in rat endometrium [ 30].
Combined treatment with GnRHa and LE provided
maximal suppression of estrogen production and reduced
inflammatory mediators in endometrial tissue. This com-
bined approach has been shown to enhance both the like-
lihood of achieving a clinical pregnancy and the chance of
live birth among women experiencing repeated implanta-
tion failure or unexplained endometriosis [ 31]. Cozzolino
et al. [ 32] reported that GnRHa monotherapy may be in-
sufficient to suppress estrogen secretion in severe adeno-
myosis, whereas combination therapy with LE was both
safe and effective. Similarly, previous studies [ 33,34] sug-
gest that combining an aromatase inhibitor with GnRHa
may improve reproductive outcomes in women with en-
dometriosis. Moreover, since endometriotic epithelial cells
harbor oncogenic mutations and endometriosis is linked to
a higher risk of ovarian cancer in ART patients [ 35], the
combination of GnRHa and LE may also reduce estrogen
exposure and help prevent malignant transformation.
In the present study, GnRHa combined with LE sig-
nificantly reduced E 2 level on the day of trigger and led to
a greater reduction in the mean diameter of OEMs than did
GnRHa alone. Notably, patients in the combination group
achieved superior reproductive outcomes, including greater
oocyte yield, increased numbers of MII oocytes, improved
fertilization rates, a higher proportion of good-quality em-
bryos on day 3, as well as enhanced clinical pregnancy rates.
We selected individuals diagnosed with OEM who ex-
hibited a normal ovarian response to minimize the influ-
ence of hyper- or hypo-response on the study outcomes.
The half-life of LE is 30–60 h, and its optimal dose in
ART remains uncertain [36]. Given that higher doses of LE
may promote multifollicular development and potentially
increase the risk of ovarian hyperstimulation and multiple
pregnancy, we adopted a commonly used low-dose regimen
of 2.5 mg/day for five days [ 37]. Although some patients
in the combination group experienced mild hypoestrogenic
symptoms, no severe adverse reactions were observed.
Limitations
This study had several limitations that should be ac-
knowledged. First, preimplantation genetic testing was not
6
performed, which may have limited a comprehensive eval-
uation of embryo quality. Second, the relatively small sam-
ple size may have limited the statistical power to detect dif-
ferences in certain outcomes. As indicated by the post hoc
power analysis, the power for several nonsignificant vari-
ables, including the number of embryos transferred and en-
dometrial thickness, was less than 20%, indicating a high
risk of type II error. Therefore, due to sample size limi-
tations, it is not possible to conclude that there is no dif-
ference between the two groups for these outcomes. The
absence of statistically significant differences should be in-
terpreted with caution, as true differences may have been
missed. Third, the optimal dose and duration of LE in this
population remain unclear and require further investigation.
Fourth, only patients with OEM were included, which may
have restricted the generalizability of the findings. Consid-
ering the heterogeneous nature of endometriosis, our results
may not be directly applicable to other subtypes, such as
deep infiltrating or peritoneal endometriosis. Finally, given
the retrospective design and the lack of randomization, po-
tential selection bias cannot be entirely excluded.
5. Conclusions
For patients with OEMs and normal ovarian response,
pretreatment with a combination of GnRHa and LE ap-
peared to be more beneficial for reducing cyst size and
improving IVF-ET pregnancy outcomes than did pretreat-
ment with GnRHa alone. Large-scale randomized con-
trolled studies are needed in order to validate these findings.
Availability of Data and Materials
The datasets generated and analyzed during the cur-
rent study are available from the corresponding author upon
reasonable request.
Author Contributions
YC and YY were involved in data interpretation. JG
contributed substantially to the acquisition, curation, verifi-
cation, and interpretation of the clinical data. QS conceived
the study and performed the data analysis. All authors par-
ticipated in manuscript revision, approved the final version,
and agree to be accountable for all aspects of the work.
Ethics Approval and Consent to Participate
This study adhered to the principles of the Declara-
tion of Helsinki and received approval from the Reproduc-
tive Medicine Ethics Committee of Xuzhou Central Hospi-
tal (Approval No. XZXY -LS-20250624-002). The require-
ment for written informed consent was waived by the Ethics
Committee due to the retrospective nature of the study.
Acknowledgment
We sincerely thank all individuals who contributed to
the preparation of this manuscript. We are also grateful to
the peer reviewers for their valuable comments and con-
structive suggestions.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflicts of interest.
Supplementary Material
Supplementary material associated with this article
can be found, in the online version, at https://doi.org/10.
31083/CEOG50028.
References
[1] Horne AW, Missmer SA. Pathophysiology, diagnosis, and man-
agement of endometriosis. BMJ. 2022; 379: e070750. https:
//doi.org/10.1136/bmj-2022-070750
[2] Hodgson RM, Lee HL, Wang R, Mol BW, Johnson N. Interven-
tions for endometriosis-related infertility: a systematic review
and network meta-analysis. Fertility and Sterility. 2020; 113:
374–382.e2. https://doi.org/10.1016/j.fertnstert.2019.09.031
[3] Sallam HN, Garcia-V elasco JA, Dias S, Arici A. Long-term pi-
tuitary down-regulation before in vitro fertilization (IVF) for
women with endometriosis. The Cochrane Database of System-
atic Reviews. 2006; 2006: CD004635. https://doi.org/10.1002/
14651858.CD004635.pub2
[4] Hao H, Li M, Zhang C, Zhang S. The effect of gonadotropin-
releasing hormone agonist downregulation in conjunction
with hormone replacement therapy on endometrial prepara-
tion in patients for frozen-thawed embryo transfer. Frontiers
in Medicine. 2024; 11: 1412126. https://doi.org/10.3389/fmed
.2024.1412126
[5] Clemenza S, V annuccini S, Ruotolo A, Capezzuoli T, Pe-
traglia F. Advances in targeting estrogen synthesis and recep-
tors in patients with endometriosis. Expert Opinion on Investi-
gational Drugs. 2022; 31: 1227–1238. https://doi.org/10.1080/
13543784.2022.2152325
[6] Agarwal SK, Foster WG. Reduction in Endometrioma Size with
Three Months of Aromatase Inhibition and Progestin Add-Back.
BioMed Research International. 2015; 2015: 878517. https://do
i.org/10.1155/2015/878517
[7] Timmerman D, V alentin L, Bourne TH, Collins WP , V errelst
H, V ergote I, et al. Terms, definitions and measurements to de-
scribe the sonographic features of adnexal tumors: a consensus
opinion from the International Ovarian Tumor Analysis (IOTA)
Group. Ultrasound in Obstetrics & Gynecology: the Official
Journal of the International Society of Ultrasound in Obstetrics
and Gynecology. 2000; 16: 500–505. https://doi.org/10.1046/j.
1469-0705.2000.00287.x
[8] La Marca A, Sunkara SK. Individualization of controlled ovar-
ian stimulation in IVF using ovarian reserve markers: from the-
ory to practice. Human Reproduction Update. 2014; 20: 124–
140. https://doi.org/10.1093/humupd/dmt037
[9] Chen ZJ, Liu JY , Huang HF, Qiao J, Zhou CQ, Huang GN,
et al. Guidelines for the diagnosis and treatment of infertility.
Chinese Journal of Obstetrics and Gynecology. 2019; 54: 505–
511. https://doi.org/10.3760/cma.j.issn.0529-567x.2019.08.001
(In Chinese)
[10] Lang JH, Leng JH, Y ang Q, Li R, Hua KQ, Zhang GN, et al. Chi-
nese Expert Consensus on GnRH-a in Obstetrics and Gynecol-
ogy. Zhonghua Fu Chan Ke Za Zhi. 2025; 60: 913–925. https://
doi.org/10.3760/cma.j.cn112141-20250529-00244 (In Chinese)
[11] Alpha Scientists in Reproductive Medicine and ESHRE Special
Interest Group of Embryology. The Istanbul consensus work-
shop on embryo assessment: proceedings of an expert meeting.
7
Human Reproduction. 2011; 26: 1270–1283. https://doi.org/10.
1093/humrep/der037
[12] Sun Q, Cao Y , Gu J, Xu Y . The application of progesterone-
primed ovarian stimulation protocol in patients with ovar-
ian endometriosis combined with diminished ovarian reserve.
BMC Women’s Health. 2025; 25: 70. https://doi.org/10.1186/
s12905-025-03601-w
[13] Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara
O, Mansour R, Nygren K, et al. The International Committee
for Monitoring Assisted Reproductive Technology (ICMART)
and the World Health Organization (WHO) Revised Glossary
on ART Terminology, 2009. Human Reproduction. 2009; 24:
2683–2687. https://doi.org/10.1093/humrep/dep343
[14] Penzer AJ, Schweikart SJ. Using Policy and Law to Help Reduce
Endometriosis Diagnostic Delay. AMA Journal of Ethics. 2025;
27: E104–109. https://doi.org/10.1001/amajethics.2025.104
[15] Hashemi M, Mohseni H, Ghahiri A, Rouholamin S. Laparo-
scopic and Hysteroscopic Findings in A Selected Group of
Women with Unexplained Infertility: A Cross-Sectional Study.
International Journal of Fertility & Sterility. 2024; 18: 339–343.
https://doi.org/10.22074/ijfs.2023.2005476.1484
[16] Latif S, Khanjani S, Saridogan E. Endometriosis and In Vitro
Fertilization. Medicina. 2024; 60: 1358. https://doi.org/10.3390/
medicina60081358
[17] Oral E, Arici A, Olive DL, Huszar G. Peritoneal fluid from
women with moderate or severe endometriosis inhibits sperm
motility: the role of seminal fluid components. Fertility
and Sterility. 1996; 66: 787–792. https://doi.org/10.1016/
s0015-0282(16)58637-3
[18] Liu Y , Luo L, Zhao H. Changes of tumor necrosis factor al-
pha and interleukin-6 levels in peritoneal fluid of patients with
endometriosis and their effects on human sperm motility and
mouse embryo development. Zhonghua Fu Chan Ke Za Zhi.
2000; 35: 332–334. (In Chinese)
[19] Paffoni A, Bolis V , Ferrari S, Benaglia L, V ercellini P ,
Somigliana E. The Gametotoxic Effects of the Endometrioma
Content: Insights From a Parthenogenetic Human Model. Re-
productive Sciences. 2019; 26: 573–579. https://doi.org/10.
1177/1933719118777637
[20] V eth VB, van de Kar MM, Duffy JM, van Wely M, Mija-
tovic V , Maas JW. Gonadotropin-releasing hormone analogues
for endometriosis. The Cochrane Database of Systematic Re-
views. 2023; 6: CD014788. https://doi.org/10.1002/14651858.
CD014788.pub2
[21] Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel
L, et al. ESHRE guideline: endometriosis. Human Reproduction
Open. 2022; 2022: hoac009. https://doi.org/10.1093/hropen/hoa
c009
[22] Sõritsa D, Saare M, Laisk-Podar T, Peters M, Sõritsa A, Matt
K, et al. Pregnancy rate in endometriosis patients according to
the severity of the disease after using a combined approach of
laparoscopy, GnRH agonist treatment and in vitro fertilization.
Gynecologic and Obstetric Investigation. 2015; 79: 34–39. http
s://doi.org/10.1159/000365329
[23] Filindris T, Papakonstantinou E, Keramida M, Panteris E,
Kalogeropoulos S, Georgopoulos N, et al. The effect of GnRH-
a on the angiogenesis of endometriosis. Hormones. 2024; 23:
509–515. https://doi.org/10.1007/s42000-024-00559-6
[24] Tamura H, Takasaki A, Nakamura Y , Numa F, Sugino N. A pilot
study to search possible mechanisms of ultralong gonadotropin-
releasing hormone agonist therapy in IVF-ET patients with en-
dometriosis. Journal of Ovarian Research. 2014; 7: 100. https:
//doi.org/10.1186/s13048-014-0100-8
[25] Li L, Liu L, Kou Z, Huo M, An J, Zhang X. GnRH agonist
treatment regulates IL-6 and IL-11 expression in endometrial
stromal cells for patients with HRT regiment in frozen em-
bryo transfer cycles. Reproductive Biology. 2022; 22: 100608.
https://doi.org/10.1016/j.repbio.2022.100608
[26] Panagodimou EK, Kalogeropoulos S, Adonakis G, Kaponis A.
Does Gonadotropin-Releasing Hormone Agonist Administra-
tion Before Assisted Reproduction Techniques Improve Preg-
nancy Rates in Women With Endometriosis? Obstetrical &
Gynecological Survey. 2024; 79: 421–428. https://doi.org/10.
1097/OGX.0000000000001283
[27] Suzuki R, Horage-Okutsu Y , Kawahara T, Nakamura K, Shi-
raishi E, Iwahata H, et al. The effect of aromatase inhibitor
on controlled ovarian stimulation for oocyte cryopreservation
in adolescent and young cancer patients. The Journal of Ob-
stetrics and Gynaecology Research. 2023; 49: 973–979. https:
//doi.org/10.1111/jog.15535
[28] Shapira M, Orvieto R, Lebovitz O, Nahum R, Aizer A,
Segev-Zahav A, et al. Does daily co administration of go-
nadotropins and letrozole during the ovarian stimulation im-
prove IVF outcome for poor and sub optimal responders? Jour-
nal of Ovarian Research. 2020; 13: 66. https://doi.org/10.1186/
s13048-020-00666-z
[29] Elgindy EA, Abdelghany AA, Sibai AbdAlsalam H, Mostafa
MI. The novel incorporation of aromatase inhibitor in hormonal
replacement therapy cycles: a randomized controlled trial. Re-
productive Biomedicine Online. 2022; 44: 641–649. https://doi.
org/10.1016/j.rbmo.2021.10.025
[30] Zhang J, Wang L, Li C, Zhang H, Li R, Li M. Letrozole pro-
motes the expression of integrin αvβ3 and HOXA10 in en-
dometrium of endometriosis. Systems Biology in Reproduc-
tive Medicine. 2022; 68: 121–128. https://doi.org/10.1080/
19396368.2021.2013577
[31] Steiner N, Shrem G, Tannus S, Dahan SY , Balayla J,
V olodarsky-Perel A, et al. Effect of GnRH agonist and letrozole
treatment in women with recurrent implantation failure. Fertil-
ity and Sterility. 2019; 112: 98–104. https://doi.org/10.1016/j.fe
rtnstert.2019.03.021
[32] Cozzolino M, Pellicer N, Galliano D, Pellicer A. Pituitary
suppression with GnRH agonists before ART may be insuffi-
cient to treat women with severe adenomyosis. Reproductive
Biomedicine Online. 2023; 46: 150–155. https://doi.org/10.
1016/j.rbmo.2022.09.023
[33] Piedimonte S, V olodarsky-Perel A, Tannus S, Tan SL, Dahan
MH. Pretreatment with a gonadotropin-releasing hormone ag-
onist and an aromatase inhibitor may improve outcomes in in
vitro fertilization cycles of women with stage I-II endometrio-
sis. F&S Science. 2020; 1: 98–103. https://doi.org/10.1016/j.xf
ss.2020.06.005
[34] Cantor A, Tannus S, Son WY , Tan SL, Dahan MH. A com-
parison of two months pretreatment with GnRH agonists with
or without an aromatase inhibitor in women with ultrasound-
diagnosed ovarian endometriomas undergoing IVF. Reproduc-
tive Biomedicine Online. 2019; 38: 520–527. https://doi.org/10.
1016/j.rbmo.2018.12.028
[35] Y oshihara K. Pathogenesis of endometrium-related diseases
based on genomic alterations in normal uterine endometrium.
The Journal of Obstetrics and Gynaecology Research. 2023; 49:
2023–2030. https://doi.org/10.1111/jog.15680
[36] Pritts EA. Letrozole for ovulation induction and controlled ovar-
ian hyperstimulation. Current Opinion in Obstetrics & Gynecol-
ogy. 2010; 22: 289–294. https://doi.org/10.1097/GCO.0b013e
32833beebf
[37] Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito
H. No increased risk of major congenital anomalies or adverse
pregnancy or neonatal outcomes following letrozole use in as-
sisted reproductive technology. Human Reproduction. 2017; 32:
125–132. https://doi.org/10.1093/humrep/dew280
8
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.